In 2003 licensed productions accou...

In 2003 licensed productions accounted for more than $70 billion in receiptss for the top 20 global pharma companies. And according to research by dint of Wood Mackenzie, that figure will top $100 billion by dint of 2008 and will portray nearly a third of the industry's total delineate ed revenue. By these measures, licensing is and will continue to be big business for Big Pharma. In fact, about companies embrace it as their core business unravelling strategy. This article highlights a certain quantity of of the findings of a 2004 cogitation that reviews the evolution of Big Pharma's R&D licensing strategies during the